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Background: 
Infertility is defined by WHO as ‘‘a disease of the reproductive system defined by the failure to achieve 
a clinical pregnancy after 12 months or more of regular unprotected sexual intercourse’’. The first and 
second line treatments for infertility are simple hormonal stimulation and assisted reproductive 
technologies, respectively. The use of these treatments could concern a large proportion of couples 
but, in France as elsewhere, lack of data on simple hormonal stimulation is a major barrier to exploring 
this issue. Our objective was to explore use of infertility treatments in the French population. 
Methods: 
Using data from the French national health insurance system, a cohort (the EGB) was implemented in 
2005. It includes 500,000 randomly selected participants and constitutes a representative sample of 
the French population. All health care consumption of these participants is prospectively recorded. For 
the present study, women participants aged 20-49 years between 2007 and 2017 were extracted (n = 
190,312) and explored for use of infertility treatments. 
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Results: 
In our representative sample of women aged 20-49 years, 4.21% [4.12-4.30] were treated for infertility 
between 2007 and 2017. Use of infertility treatments varied according to the womens’ age: 0.88% 
[0.81-0.95] at age 20-24; 3.34% [3.20- 3.47] at 25-29; 4.35% [4.20-4.50] at 30-34; 3.30% [3.17-3.43] at 
35-39; 1.84% [1.74-1.94] at 40-44; 0.34% [0.30-0.38] at 45-49. Further analysis will describe care 
pathways and explore the different treatments for infertility followed by each woman. The association 
between age and care pathways will be tested. 
Conclusions: 
Taking advantage of data from the French national health insurance system, our work explores for the 
first time use of infertility treatment in a large representative sample. It shows that infertility treatment 
has an important public health impact with more than 4% of women aged 20-49 years treated for 
infertility. 
Key messages: 
 Our work explores for the first time the use of all treatments for infertility by including not only 
assisted reproductive treatments but also simple hormonal stimulation. 
 Data from the French health insurance system are currently opening to research and are a 
promising source to address topics previously unexplored because of a lack of reliable medical 
care data. 
